# Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol

> **NCT02905981** · PHASE2 · TERMINATED · sponsor: **Rockwell Medical Technologies, Inc.** · enrollment: 1 (actual)

## Conditions studied

- Iron-Refractory Iron-Deficiency Anemia

## Interventions

- **DRUG:** Fer-In-Sol
- **DRUG:** Shohl's solution
- **DRUG:** Triferic

## Key facts

- **NCT ID:** NCT02905981
- **Lead sponsor:** Rockwell Medical Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-17
- **Primary completion:** 2018-03-15
- **Final completion:** 2018-03-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Limited subjects, patient compliance
- **Last updated:** 2020-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02905981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02905981, "Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02905981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*